![Routine Trial-and-Error Approach to Protein Formulation Is Not Sufficient to Establish Obviousness Absent a Reasonable Expectation of Success in Achieving the Claimed Formulation, <i>PTAB Litigation Blog</i>](/-/media/images/publications/2017/01/routine-trialanderror-approach-to-protein-formulat/extensionceogimageoverride/trialerrorog.jpg?rev=c09130716b93401d9f1e3088ab12abc1&sc_lang=en&la=en&h=112&w=180&hash=8A227990B9E808F028D611C773E0A612)
Routine Trial-and-Error Approach to Protein Formulation Is Not Sufficient to Establish Obviousness Absent a Reasonable Expectation of Success in Achieving the Claimed Formulation, PTAB Litigation Blog
Visit the Jones Day PTAB Litigation Blog.
On December 22, 2016, in a final written decision in IPR2015-01537, the PTAB rejected an obviousness challenge brought by Momenta Pharmaceuticals, Inc. against a patent owned by Bristol-Myers Squibb directed to certain stable liquid formulations of the therapeutic molecule CTLA4Ig (a fusion protein commercially available as Orencia) for subcutaneous delivery.
Read the full article at ptablitigationblog.com.